Loading stock data…
$48.91-0.09 (-0.18%)
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders.
MBX Biosciences, Inc. in the Healthcare sector is trading at $48.91 with a market capitalization of $2.8B. Wall Street consensus targets $95.70 (10 analysts), implying a +95.7% move over the next 12 months. The stock is currently 33% below its 52-week high of $72.64, remaining 10.1% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$40.93M↓ | -$27.27M↓ | -$25.80M↓ | -$23.93M↓ | -$21.80M |
| Net Income | -$37.09M↓ | -$23.52M↓ | -$22.06M↓ | -$21.62M↓ | -$19.41M |
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is Canvuparatide (MBX 2109),...